^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mulnitorsen (Andes-1537)

    i
    Other names: Andes-1537, Andes 1537
    Associations

    News

    Trials
    Company:
    Andes Biotech
    Drug class:
    Apoptosis inducer, ncmtRNA interference
    Related drugs:
    Associations

    News

    Trials
    2years
    Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=67, Completed, Andes Biotechnologies | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    RAS wild-type • NRAS wild-type
    |
    mulnitorsen (Andes-1537)
    over2years
    Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=67, Active, not recruiting, Andes Biotechnologies | Recruiting --> Active, not recruiting | N=139 --> 67 | Trial completion date: Nov 2022 --> Apr 2022
    Enrollment closed • Enrollment change • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    RAS wild-type • NRAS wild-type
    |
    mulnitorsen (Andes-1537)
    over2years
    Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=139, Recruiting, Andes Biotechnologies | Trial completion date: Sep 2021 --> Nov 2022 | Trial primary completion date: Sep 2021 --> Apr 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    RAS wild-type • NRAS wild-type
    |
    mulnitorsen (Andes-1537)
    3years
    Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=124, Recruiting, Andes Biotechnologies | Trial completion date: Apr 2021 --> Sep 2021 | Trial primary completion date: Apr 2021 --> Sep 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    mulnitorsen (Andes-1537)
    4years
    Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=144, Recruiting, Andes Biotechnologies | Active, not recruiting --> Recruiting
    Clinical • Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    mulnitorsen (Andes-1537)
    4years
    Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=144, Active, not recruiting, Andes Biotechnologies | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    mulnitorsen (Andes-1537)
    4years
    Targeting antisense mitochondrial noncoding RNAs induces bladder cancer cell death and inhibition of tumor growth through reduction of survival and invasion factors. (PubMed, J Cancer)
    Similarly, treatment of a high-grade bladder cancer PDX with Andes-1537S resulted in a strong inhibition of tumor growth. Our results suggest that ASncmtRNAs could be potent targets for bladder cancer as adjuvant therapy.
    Journal
    |
    BCL2L1 (BCL2-like 1) • BIRC5 (Baculoviral IAP repeat containing 5) • CASP3 (Caspase 3)
    |
    mulnitorsen (Andes-1537)